April 16, 2018 Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path
March 28, 2018 C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foun
March 24, 2018 Global Health Partners Accelerate Uptake of Genetic Sequencing for Surveillance And Diagnosis Of Drug-Resistant Tuberculosis WHO adopts ReSeqTB as bioinformatics platform for TB surveillance, enabling the global scale-up of culture-free,
March 14, 2018 Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin
February 28, 2018 Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices
February 20, 2018 2018 ISCTM Distinguished Poster Award Winner: “Global Regulatory Agencies Support Dopamine Transporter Neuroimaging in Clinical Trials Targeting Parkinson’s disease”
February 12, 2018 Tucson-based Critical Path Institute emerging as top drug-research organization President and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published Februa
February 5, 2018 Critical Path to TB Drug Regimens (CPTR) 2018 Annual Workshop, postponed Critical Path Institute and Bill & Melinda Gates Foundation have decided to postpone the Critical Path to TB Drug Regimens Wor
February 1, 2018 Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
January 22, 2018 Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort